Important notice

Meds75+ – information regarding the use for persons aged 75+

Substances A-Z
  • Va

  • Valsartanum
    Class A
    Suitable for older persons. Monitor renal function during the pharmacotherapy. Avoid concurrent use of anti-inflammatory analgesics.
  • Ve

  • Verapamili hydrochloridum
    Class D
    Avoid use in older persons. Use only in special cases. Reduce the dose in even moderate renal insufficiency. Significant adverse effects include bradycardia, constipation, cardiac insufficiency and swelling. Take interactions into account, especially with digoxin and beta blockers. Avoid consuming grapefruit during treatment.
  • Vi

  • Vilanterolum
    Class A
    Suitable for older persons. Potentiates sympathomimetic effects. May cause hypokalaemia.
  • Vildagliptinum
    Class C
    Suitable for older persons, with specific cautions. Not suitable for patients with hepatic insufficiency. Reduce the dose in even moderate renal insufficiency.

Icon explanation

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on Mar 30, 2021.